BioMark Diagnostics Inc.
BUX
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -9.84% | -10.51% | -5.41% | 0.34% | 12.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -9.84% | -10.51% | -5.41% | 0.34% | 12.13% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -9.84% | -10.51% | -5.41% | 0.34% | 12.13% |
| SG&A Expenses | -10.12% | 15.20% | 95.28% | 2.46% | -37.35% |
| Depreciation & Amortization | -42.74% | -36.89% | -44.69% | -1.58% | 9.77% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.41% | 32.68% | 34.21% | -8.89% | 6.97% |
| Operating Income | 31.34% | -37.12% | -38.03% | 9.62% | -6.41% |
| Income Before Tax | 20.00% | -155.77% | -46.09% | 21.74% | -3.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.00% | -155.77% | -46.09% | 21.74% | -3.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.00% | -155.77% | -46.09% | 21.74% | -3.10% |
| EBIT | 31.34% | -37.12% | -38.03% | 9.62% | -6.41% |
| EBITDA | 31.76% | -37.33% | -38.34% | 9.73% | -6.47% |
| EPS Basic | 91.43% | -131.58% | -35.14% | 24.44% | 0.00% |
| Normalized Basic EPS | 90.91% | -133.33% | -34.78% | 25.00% | 0.00% |
| EPS Diluted | 91.43% | -131.58% | -35.14% | 24.44% | 0.00% |
| Normalized Diluted EPS | 90.91% | -133.33% | -34.78% | 25.00% | 0.00% |
| Average Basic Shares Outstanding | 938.55% | 9.13% | 9.13% | 2.97% | 2.97% |
| Average Diluted Shares Outstanding | 938.55% | 9.13% | 9.13% | 2.97% | 2.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |